Dyadic International (NASDAQ:DYAI) Major Shareholder Francisco Trust Under Agreemen Sells 40,000 Shares

Dyadic International Inc. (NASDAQ:DYAI) major shareholder Francisco Trust Under Agreemen sold 40,000 shares of the company’s stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $1.98, for a total value of $79,200.00. Following the completion of the sale, the insider owned 3,410,664 shares in the company, valued at $6,753,114.72. The trade was a 1.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Dyadic International Stock Up 5.3%

DYAI stock opened at $1.02 on Tuesday. The business has a 50 day moving average of $0.77 and a 200 day moving average of $0.83. The firm has a market cap of $37.13 million, a PE ratio of -4.43 and a beta of 1.15. Dyadic International Inc. has a twelve month low of $0.65 and a twelve month high of $1.35. The company has a quick ratio of 2.42, a current ratio of 2.42 and a debt-to-equity ratio of 4.08.

Dyadic International (NASDAQ:DYAI) last released its earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Dyadic International had a negative return on equity of 1,005.45% and a negative net margin of 192.40%.The company had revenue of $1.11 million during the quarter, compared to the consensus estimate of $0.90 million. On average, research analysts forecast that Dyadic International Inc. will post 0.13 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Dyadic International in a report on Wednesday, June 24th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $3.00.

Institutional Trading of Dyadic International

Hedge funds have recently bought and sold shares of the company. Marathon Capital Management bought a new stake in shares of Dyadic International during the 3rd quarter valued at about $41,000. Bank of America Corp DE boosted its stake in shares of Dyadic International by 16,146.7% during the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 26,965 shares during the last quarter. Landscape Capital Management L.L.C. bought a new position in Dyadic International in the 3rd quarter worth $190,000. Geode Capital Management LLC grew its holdings in Dyadic International by 13.7% during the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after purchasing an additional 36,266 shares during the period. Finally, Apis Capital Advisors LLC bought a new stake in Dyadic International during the third quarter valued at about $1,817,000. Hedge funds and other institutional investors own 27.95% of the company’s stock.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.